Nebenwirkungen · Taxotere
TAXOTERE 20 mg/0.5 mL concentrate and solvent for solution for infusion · Abschnitt 4.8 · PDF-Seite 15–16
HOS-084571 · Präparat HOS-083047
15 MedDRA system organ classes Very common adverse Common adverse reactions reactions Immune system disorders Hypersensitivity (no severe) Metabolism and nutrition Anorexia disorders Nervous system disorders Peripheral sensory neuropathy Peripheral motor neuropathy (G3/4: 0.8%) (G3/4: 2.5%) Cardiac disorders Arrhythmia (no severe) Vascular disorders Hypotension Gastrointestinal disorders Nausea (G3/4: 3.3%); Constipation Stomatitis (G3/4: 1.7%); Vomiting (G3/4: 0.8%); Diarrhoea (G3/4: 1.7%) Skin and subcutaneous tissue Alopecia; Nail disorders (severe: 0.8%) disorders Skin reaction (G3/4: 0.8%) Musculoskeletal and connective Myalgia tissue disorders General disorders and Asthenia (severe: 12.4%); administration site conditions Fluid retention (severe: 0.8%); Pain Investigations G3/4 Blood bilirubin increased (< 2%)
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-10-22T16:45:00Z · SHA-256 518a48b73ebbaf067647805c9944cdf9fe7e9826b63e3719c8c44fa589fb5cce · Passage 7da44d460f32b38a42d999530d2e1e018c4a6a216393555b5e731cf2ffef7d8f · Zeichen 10898–12343 im Abschnitt